DK2257263T3 - Topiske formuleringer til forebyggelse af seksuelt overførte sygdomme og fremgangsmåder til fremstilling heraf - Google Patents
Topiske formuleringer til forebyggelse af seksuelt overførte sygdomme og fremgangsmåder til fremstilling heraf Download PDFInfo
- Publication number
- DK2257263T3 DK2257263T3 DK08744462.6T DK08744462T DK2257263T3 DK 2257263 T3 DK2257263 T3 DK 2257263T3 DK 08744462 T DK08744462 T DK 08744462T DK 2257263 T3 DK2257263 T3 DK 2257263T3
- Authority
- DK
- Denmark
- Prior art keywords
- weight
- concentration
- dimethicone
- ceteareth
- oil
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 208000019802 Sexually transmitted disease Diseases 0.000 title description 20
- 239000012049 topical pharmaceutical composition Substances 0.000 title description 8
- 230000002265 prevention Effects 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims description 61
- 238000009472 formulation Methods 0.000 claims description 36
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 32
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 32
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 28
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 18
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 18
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 18
- 229960000541 cetyl alcohol Drugs 0.000 claims description 16
- 229940008099 dimethicone Drugs 0.000 claims description 16
- 239000011787 zinc oxide Substances 0.000 claims description 16
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 15
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 15
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 230000004888 barrier function Effects 0.000 claims description 13
- 230000005540 biological transmission Effects 0.000 claims description 13
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 13
- 229940082337 dimethicone 20 Drugs 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 230000001681 protective effect Effects 0.000 claims description 13
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 13
- 229940073669 ceteareth 20 Drugs 0.000 claims description 12
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 12
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 244000000033 sexually transmitted pathogen Species 0.000 claims description 10
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 9
- 229940031955 anhydrous lanolin Drugs 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 6
- 208000009889 Herpes Simplex Diseases 0.000 claims description 6
- 244000052613 viral pathogen Species 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 3
- 239000004166 Lanolin Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000007970 homogeneous dispersion Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 229940039717 lanolin Drugs 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 238000010952 in-situ formation Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000010791 quenching Methods 0.000 claims 1
- BILPUZXRUDPOOF-UHFFFAOYSA-N stearyl palmitate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC BILPUZXRUDPOOF-UHFFFAOYSA-N 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 239000003974 emollient agent Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- -1 polydimethylsiloxane Polymers 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 231100000344 non-irritating Toxicity 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- 239000002344 surface layer Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003641 microbiacidal effect Effects 0.000 description 2
- 229940124561 microbicide Drugs 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000056 polyoxyethylene ether Polymers 0.000 description 2
- 239000011252 protective cream Substances 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000014599 transmission of virus Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000002398 hexadecan-1-ols Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000011328 necessary treatment Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000013520 petroleum-based product Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical group [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001150 spermicidal effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940100617 topical lotion Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Claims (12)
1. Olie-i-vand-formulering til inhibering af overførsel af seksuelt overførte patogener, kendetegnet ved forbedrede hudbeskyttelsesegenskaber, hvilken formulering består af en kombination af: (1) dimethicone 20, i området fra 10,0 til 20,0 vægt-%; (2) dimethicone 12500, i området fra 3,0 til 10,0 vægt-%; (3) zinkoxid, i området fra 1,0 til 8,0 vægt-%; (4) en blanding af cetearylalkohol og ceteareth-20, i området fra 6,0 til 10,0 vægt-%; (5) glycerin, i området fra 2,0 til 10,0 vægt-%; (6) ceteareth-12, i området fra 0,5 til 3,0 vægt-%; (7) dinatriumedetat, i området fra 0,01 til 0,1 vægt-%; (8) benzalkoniumchlorid, i området fra 0,01 til 0,25 vægt-%; (9) vandfri lanolin, i området fra 0,5 til 3,0 vægt-%; (10) cetostearylalkohol, i området fra 1,0 til 5,0 vægt-%; (11) cetylalkohol, i området fra 1,0 til 5,0 vægt-%; og (12) en tilstrækkelig mængde deioniseret vand til at danne formuleringen; hvor kontakt med huden fører til in situ-dannelse af et hudbeskyttende barrierelag, og hvor de seksuelt overførte patogener er virale patogener.
2. Olie-i-vand-formulering ifølge krav 1, der består af en kombination af: (1) dimethicone 20 i en koncentration på ca. 15,0 vægt-%; (2) dimethicone 12500 i en koncentration på ca. 5,0 vægt-%; (3) zinkoxid i en koncentration på ca. 2,0 vægt-%; (4) en blanding af cetearylalkohol og ceteareth-20 i en koncentration på ca. 8,0 vægt-%; (5) glycerin i en koncentration på ca. 5,0 vægt-%; (6) ceteareth-12 i en koncentration på ca. 1,0 vægt-%; (7) dinatriumedetat i en koncentration på ca. 0,05 vægt-%; (8) benzalkoniumchlorid i en koncentration på ca. 0,2 vægt-%; (9) vandfri lanolin i en koncentration på ca. 1,0 vægt-%; (10) cetostearylalkohol i en koncentration på ca. 3,0 vægt-%; (11) cetylalkohol i en koncentration på ca. 2,0 vægt-%; og (12) en tilstrækkelig mængde deioniseret vand til at danne formuleringen.
3. Olie-i-vand-formulering ifølge krav 1, der består af en kombination af: (1) dimethicone 20 i en koncentration på ca. 15,0 vægt-%; (2) dimethicone 12500 i en koncentration på ca. 5,0 vægt-%; (3) zinkoxid i en koncentration på ca. 5,0 vægt-%; (4) en blanding af cetearylalkohol og ceteareth-20 i en koncentration på ca. 7,0 vægt-%; (5) glycerin i en koncentration på ca. 8,0 vægt-%; (6) ceteareth-12 i en koncentration på ca. 1,0 vægt-%; (7) dinatriumedetat i en koncentration på ca. 0,5 vægt-%; (8) benzalkoniumchlorid i en koncentration på ca. 0,2 vægt-%; (9) vandfri lanolin i en koncentration på ca. 1,0 vægt-%; (10) cetostearylalkohol i en koncentration på ca. 3,0 vægt-%; (11) cetylalkohol i en koncentration på ca. 2,0 vægt-%; og (12) en tilstrækkelig mængde deioniseret vand til at danne formuleringen.
4. Olie-i-vand-formulering ifølge krav 1, hvor formuleringen omfatter en vandfase, der omfatter (1) DEIONISERET VAND (USP) i tilstrækkelige mængder til at opløse bestanddelene 2-5; (2) DINATRIUMEDETAT 0,01 - 0,1 (3) BENZALKONIUMCHLORID 0,01 - 0,25 (4) ZINKOXID 1,0 - 8,0 (5) GLYCERIN (USP) 2,0 - 10,0 og en oliefase, der omfatter (6) DIMETHICONE 20 10,0 - 20,0 (7) DIMETHICONE 12500 3,0 - 10,0 (8) CETEARYLALKOHOL og/eller CETEARETH-20 6,0 - 10,0 (9) CETEARETH-12 0,5 - 3,0 (10) VANDFRI LANOLIN 0,5 - 3,0 (11) CETOSTEARYLALKOHOL 1,0 - 5,0 (12) CETYLALKOHOL 1,0 - 5,0.
5. Olie-i-vand-formulering ifølge et hvilket som helst af kravene 1 til 4, hvor formuleringen er en creme.
6. Olie-i-vand-formulering ifølge et hvilket som helst af kravene 1 til 5, hvor det virale patogen er valgt fra herpes simplex vims type 1 (HSV-1), herpes simplex vims type 2 (HSV-2) og human immundeficiensvims (HIV).
7. Fremgangsmåde til dannelse af en olie-i-vand-formulering bestående af: en vandfase, der omfatter (i vægt-%) (1) deioniseret vand (USP) i tilstrækkelige mængder til at indarbejde bestanddelene 2-5 deri; (2) dinatriumedetat 0,01 - 0,1 (3) benzalkoniumchlorid 0,01 - 0,25 (4) zinkoxid 1,0 - 8,0 (5) glycerin (USP) 2,0 - 10,0 og en oliefase, der omfatter (i vægt-%) (6) dimethicone 20 10,0 - 20,0 (7) dimethicone 12500 3,0 - 10,0 (8) cetearylalkohol og/eller ceteareth-20 6,0 - 10,0 (9) ceteareth-12 0,5 - 3,0 (10) vandfri lanolin 0,5 - 3,0 (11) cetostearylalkohol 1,0 - 5,0 (12) cetylalkohol 1,0 - 5,0. hvor olie-i-vand-formuleringen er fremstillet i henhold til følgende trin:
1. Opvarmning til 75 °C af dimethicone 20, dimethicone 12500, cetearylalkohol, ceteareth-20, ceteareth-12, vandfri lanolin, cetostearylalkohol og cetylalkohol for at tillade materialerne at smelte;
2. Opløsning af dinatriumedetat i det deioniserede vand;
3. Tilsætning af benzalkoniumchlorid til trin 2;
4. Opvarmningstrin 3 til 75-78 °C;
5. Dispergering af zinkoxid i glycerin for at danne en homogen dispersion;
6. Med højhastighedsblanding, langsom tilsætning af materialerne fra trin 4 (vandfase) til materialerne fra trin 1 (oliefase) og begyndende afkøling;
7. Når der nås 60 °C, tilføjelse af dispersionen fra trin 5 til materialerne ffa trin 6.
8. Når der nås 50 °C, reducering af blandingshastigheden;
9. Når der nås 40 °C, yderligere reducering af blandingshastigheden;
10. Når der nås 25 °C, afbrydelse af blandingen.
8. Olie-i-vand-formulering ifølge et hvilket som helst af kravene 1 til 5 til anvendelse i inhiberingen af overførsel af seksuelt overførte patogener, hvor de seksuelt overførte patogener er virale patogener.
9. Olie-i-vand-formulering ifølge krav 8, hvor det virale patogen er valgt fra herpes simplex vims type 1 (HSV-1), herpes simplex vims type 2 (HSV-2) og human immundeficiensvims (HIV).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/038,283 US8062631B2 (en) | 2006-09-28 | 2008-02-27 | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
| PCT/US2008/058428 WO2009108210A1 (en) | 2008-02-27 | 2008-03-27 | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2257263T3 true DK2257263T3 (da) | 2014-12-01 |
Family
ID=41037581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08744462.6T DK2257263T3 (da) | 2008-02-27 | 2008-03-27 | Topiske formuleringer til forebyggelse af seksuelt overførte sygdomme og fremgangsmåder til fremstilling heraf |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8062631B2 (da) |
| EP (1) | EP2257263B1 (da) |
| AU (1) | AU2008351414B2 (da) |
| CA (1) | CA2717033C (da) |
| CY (1) | CY1116077T1 (da) |
| DK (1) | DK2257263T3 (da) |
| ES (1) | ES2524062T3 (da) |
| HR (1) | HRP20141133T1 (da) |
| HU (1) | HUE025433T2 (da) |
| NZ (2) | NZ588195A (da) |
| PL (1) | PL2257263T3 (da) |
| PT (1) | PT2257263E (da) |
| SI (1) | SI2257263T1 (da) |
| WO (1) | WO2009108210A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8257720B2 (en) * | 2009-04-20 | 2012-09-04 | Conopco, Inc. | Stabilized cationic ammonium compounds and compositions comprising the same |
| US8324255B2 (en) | 2009-09-15 | 2012-12-04 | Conopco, Inc. | Chelator stabilized cationic ammonium compounds and compositions comprising the same |
| CN103209677B (zh) | 2010-10-01 | 2015-08-19 | 玫琳凯有限公司 | 皮肤增湿剂和老化抑制配制剂 |
| CA2858372A1 (en) * | 2011-11-10 | 2013-05-16 | Lankenau Institute For Medical Research | Compositions and methods for the prevention of microbial infections |
| CA2781379C (en) * | 2012-03-26 | 2013-09-03 | Clji Ip Company, Llc | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4952411A (en) * | 1987-02-25 | 1990-08-28 | Trustees Of Columbia University In The City Of New York | Method of inhibiting the transmission of AIDS virus |
| NO178843C (no) * | 1988-07-11 | 1996-06-19 | Sspl Sa Safe Sex Prod Licens | Fremgangsmåte for fremstilling av et farmasöytisk preparat for å forhindre seksuelt overförbare sykdommer |
| US6045786A (en) * | 1989-02-01 | 2000-04-04 | Johns Hopkins University | Topical application of antibodies for prophylaxis against sexually transmitted diseases and pregnancy |
| US6328991B1 (en) * | 1992-10-21 | 2001-12-11 | John Myhling | Composition and method for prevention of sexually transmitted diseases, including aids |
| US7404967B2 (en) * | 1994-12-21 | 2008-07-29 | Cosmederm, Inc. | Topical product formulations containing strontium for reducing skin irritation |
| US6582711B1 (en) * | 1997-01-09 | 2003-06-24 | 3M Innovative Properties Company | Hydroalcoholic compositions thickened using polymers |
| US6183762B1 (en) * | 1997-05-27 | 2001-02-06 | Sembiosys Genetics Inc. | Oil body based personal care products |
| US6656928B1 (en) * | 1999-09-02 | 2003-12-02 | Mccadden Michael E. | Composition for the topical treatment of rashes, dermatoses and lesions |
| US6835717B2 (en) * | 2000-03-08 | 2004-12-28 | The Johns Hopkins University School Of Medicine | β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases |
| US6821958B1 (en) * | 2001-03-06 | 2004-11-23 | Roger K. Hershline | Antiviral composition |
| US7097828B2 (en) * | 2001-06-29 | 2006-08-29 | Schering-Plough Healthcare Products, Inc. | Sunscreen formulations containing waterborne polyurethane polymers |
| WO2003041686A2 (en) * | 2001-11-14 | 2003-05-22 | Medlogic Global Limited | Improved therapy for topical diseases |
| US7879365B2 (en) * | 2002-02-07 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Zinc salt compositions for the prevention of dermal and mucosal irritation |
| US6667026B1 (en) * | 2002-03-15 | 2003-12-23 | Pocono Falls, Inc. | Allergic contact dermatitis treatment and composition therefor |
| US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
| SI1506781T1 (da) * | 2003-11-03 | 2005-08-31 | Volkmann Peter Hansen |
-
2008
- 2008-02-27 US US12/038,283 patent/US8062631B2/en active Active
- 2008-03-27 NZ NZ588195A patent/NZ588195A/en not_active IP Right Cessation
- 2008-03-27 AU AU2008351414A patent/AU2008351414B2/en not_active Ceased
- 2008-03-27 EP EP08744462.6A patent/EP2257263B1/en active Active
- 2008-03-27 PT PT87444626T patent/PT2257263E/pt unknown
- 2008-03-27 NZ NZ600566A patent/NZ600566A/xx not_active IP Right Cessation
- 2008-03-27 DK DK08744462.6T patent/DK2257263T3/da active
- 2008-03-27 ES ES08744462.6T patent/ES2524062T3/es active Active
- 2008-03-27 SI SI200831333T patent/SI2257263T1/sl unknown
- 2008-03-27 HR HRP20141133AT patent/HRP20141133T1/hr unknown
- 2008-03-27 CA CA2717033A patent/CA2717033C/en active Active
- 2008-03-27 WO PCT/US2008/058428 patent/WO2009108210A1/en not_active Ceased
- 2008-03-27 HU HUE08744462A patent/HUE025433T2/en unknown
- 2008-03-27 PL PL08744462T patent/PL2257263T3/pl unknown
-
2011
- 2011-10-17 US US13/274,813 patent/US8409556B2/en not_active Expired - Fee Related
-
2013
- 2013-02-27 US US13/778,211 patent/US20130171089A1/en not_active Abandoned
-
2014
- 2014-09-15 US US14/486,500 patent/US20150004250A1/en not_active Abandoned
- 2014-11-17 CY CY20141100954T patent/CY1116077T1/el unknown
-
2015
- 2015-06-22 US US14/746,718 patent/US20150283173A1/en not_active Abandoned
-
2016
- 2016-01-14 US US14/996,201 patent/US20160129041A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8409556B2 (en) | 2013-04-02 |
| ES2524062T3 (es) | 2014-12-03 |
| CA2717033C (en) | 2014-03-25 |
| US20150283173A1 (en) | 2015-10-08 |
| CY1116077T1 (el) | 2017-02-08 |
| EP2257263B1 (en) | 2014-09-03 |
| WO2009108210A1 (en) | 2009-09-03 |
| PL2257263T3 (pl) | 2015-10-30 |
| US8062631B2 (en) | 2011-11-22 |
| US20120034311A1 (en) | 2012-02-09 |
| AU2008351414B2 (en) | 2013-09-12 |
| CA2717033A1 (en) | 2009-09-03 |
| NZ600566A (en) | 2013-04-26 |
| NZ588195A (en) | 2012-07-27 |
| AU2008351414A1 (en) | 2009-09-03 |
| US20160129041A1 (en) | 2016-05-12 |
| US20150004250A1 (en) | 2015-01-01 |
| US20130171089A1 (en) | 2013-07-04 |
| HRP20141133T1 (xx) | 2015-03-27 |
| EP2257263A4 (en) | 2012-06-27 |
| HUE025433T2 (en) | 2016-02-29 |
| PT2257263E (pt) | 2014-11-21 |
| SI2257263T1 (sl) | 2015-02-27 |
| US20080145452A1 (en) | 2008-06-19 |
| EP2257263A1 (en) | 2010-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2151029A1 (en) | Protective skin composition | |
| JPH11502850A (ja) | 即効性かつ持続性局所消毒剤 | |
| KR20070094958A (ko) | 아연염을 포함하는 무자극성 조성물 | |
| DK2257263T3 (da) | Topiske formuleringer til forebyggelse af seksuelt overførte sygdomme og fremgangsmåder til fremstilling heraf | |
| DK2644193T3 (da) | Topiske formuleringer til forebyggelse af seksuelt overførte sygdomme og fremgangsmåder til fremstilling heraf | |
| US8409557B2 (en) | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same | |
| US20130236565A1 (en) | Topical formulations | |
| DE69921058T2 (de) | Verwendung von Triclosan zur Behandlung und Prävention von Mukositis | |
| US20080081797A1 (en) | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same | |
| HK1189513B (en) | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same | |
| AU2012203566B1 (en) | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same | |
| NZ600568A (en) | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same and which does not include an antimicrobial / antiviral agent | |
| NZ600568B (en) | Topical formulations for the prevention of sexually transmitted disease and methods of producing the same | |
| EP3595726B1 (en) | Treatment of herpes simplex symptoms on skin and mucous membrane of mammals | |
| US20130243826A1 (en) | Topical compositions for use in the control of sexually transmitted diseases |